The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF.

about

Entacapone reduces cortical activation in Parkinson's disease with wearing-off: a f-MRI study.Causes, consequences, and cures for neuroinflammation mediated via the locus coeruleus: noradrenergic signaling system.

P2860

Q33617946-6690A207-1481-481E-B21F-409A82505C87 Q38770352-FEFB8E40-54FE-401C-954A-CB719C12B2E7

P2860

The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF.

Item

http://www.wikidata.org/entity/Q43193465

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF.

@en

The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF.

@nl

type

Item

label

The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF.

@en

The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF.

@nl

prefLabel

The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF.

@en

The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF.

@nl

P1476

The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF.

@en

P2093

Anita Kullman

http://www.w3.org/2001/XMLSchema#string

Kerstin Arstrand

http://www.w3.org/2001/XMLSchema#string

Maria Nord

http://www.w3.org/2001/XMLSchema#string

Nil Dizdar

http://www.w3.org/2001/XMLSchema#string

Peter Zsigmond

http://www.w3.org/2001/XMLSchema#string

P2860

Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment

Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.

Continuous dopamine-receptor stimulation in early Parkinson's disease.

Levodopa-induced dyskinesias.

The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease

Continuous dopaminergic stimulation in early and advanced Parkinson's disease.

Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations.

Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose

The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.

Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease.

P304

363-367

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.22613

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20077469

http://www.w3.org/2001/XMLSchema#string

P921

levodopa

The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF.

about

P2860

P2860

The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921